107 related articles for article (PubMed ID: 9810418)
1. [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Pawlicki M; Rolski J; Wiczyńska B; Rychlik U
Ginekol Pol; 1998 Jul; 69(7):580-5. PubMed ID: 9810418
[TBL] [Abstract][Full Text] [Related]
2. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
3. Advances in supportive therapy.
Facchini T
Zentralbl Gynakol; 1996; 118(10):589-90. PubMed ID: 8912478
[No Abstract] [Full Text] [Related]
4. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose PG
Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
[TBL] [Abstract][Full Text] [Related]
5. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
6. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
7. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Nagy P; Kádasi L
Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
[TBL] [Abstract][Full Text] [Related]
8. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
De Lena M; Lorusso V; Romito S
Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
[TBL] [Abstract][Full Text] [Related]
13. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Garzetti GG; Ciavattini A; Muzzioli M; Romanini C
Cancer; 1999 May; 85(10):2226-31. PubMed ID: 10326702
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil.
Mead GM; Williams CJ; Whitehouse JM
Cancer Chemother Pharmacol; 1985; 15(2):179-80. PubMed ID: 3839443
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Renody N; Mularoni E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-38-S2-40. PubMed ID: 9045335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
